Table Info

Table 2.

Nociceptive TRP channels in regulating cancer progression

Channel	Tumor types	*Tumor cells vs.* Normal controls**	Pathological function in cancer	Prognosis	Reference
TRPA1	Breast cancer, lung cancer, pancreatic cancer, nasopharyngeal carcinoma	Over-expression	Promote cancer cell survival against chemotherapeutic agents	Unfavorable in breast cancer, lung cancer, nasopharyngeal carcinoma	[82, 89, 90]
TRPC1	Breast cancer (PTEN-deficient type), lung cancer, gastric cancer, pancreatic cancer, colorectal cancer, glioblastoma	Over-expression	Promote cancer cell growth and metastasis	Unfavorable in breast cancer (PTEN-deficient type), gastric cancer	[91, 92]
TRPC3	Breast cancer (triple negative type), ovarian cancer	Over-expression	Promote cancer cell growth and cancer cell survival against chemotherapeutic agents	Unfavorable in breast cancer, ovarian cancer	[40, 93]
TRPC5	Breast cancer, colorectal cancer	Over-expression	Promote cancer cell survival against chemotherapeutic agents, tumor metastasis	Unfavorable in colorectal cancer	[94, 95]
TRPC6	Breast cancer, hepatoma, gastric cancer, ESCC, prostate cancer, glioblastoma	Over-expression	Promote cancer cell growth and metastasis	Unfavorable in esophageal squamous cell carcinoma	[96–101]
TRPC7	Lung cancer, skin sarcoma	Over-expression	Promote cancer cell growth	Not investigated	[13]
TRPM2	Breast cancer, lung cancer, gastric cancer, pancreatic cancer, prostate cancer, HCC, oral cancer, glioblastoma	Over-expression, mutant type in PDAC, long non-coding RNA TRPM2-AS in HCC	Promote cancer cell growth and metastasis	Unfavorable in luminal B and TP53 wild type breast cancer, lung cancer, PDAC, HCC (Long non-coding RNA TRPM2-AS)	[45, 102–107]
TRPM3	ccRCC, glioblastoma, choroid plexus papilloma	Over-expression	Promote cancer cell growth	Not investigated	[107–109]
TRPM8	Breast cancer, lung cancer, gastric cancer, ESCC, pancreatic cancer, prostate cancer, HCC, esophageal cancer, glioblastoma, neuroblastoma, urinary bladder carcinoma	Over-expression	Promote cancer cell survival against chemotherapeutic agents, cancer cell growth and metastasis	Unfavorable in urinary bladder carcinoma	[110–113]
TRPV1	Breast cancer, oral cancer, glioblastoma	Over-expression	Promote cancer cell growth	Unfavorable in breast cancer	[107, 114, 115]
TRPV2	Breast cancer, gastric cancer, ESCC, prostate cancer, HCC, ovarian cancer, oral cancer, glioblastoma, hematological cancer, urinary bladder carcinoma	Over-expression, full-length TRPV2 (f-TRPV2) in urinary bladder carcinoma	Promote cancer cell growth and metastasis	Unfavorable in multiple myeloma, ESCC	[46, 107, 111, 116, 117]
TRPV3	Breast cancer, lung cancer, oral cancer	Over-expression	Promote cancer cell growth and metastasis	Not investigated	[111, 116, 118]
TRPV4	Breast cancer, gastric cancer, pancreatic cancer, HCC, colorectal cancer, oral cancer, glioblastoma	Over-expression	Promote cancer cell growth and metastasis	Unfavorable in gastric cancer	[93, 111, 116, 119–122]

ESCC: esophageal squamous cell carcinoma; PTEN: phosphatase and Tensin Homolog deleted on Chromosome 10; PDAC: pancreatic ductal adenocarcinoma; HCC: hepatocellular carcinoma; ccRCC: clear cell renal cell carcinoma

Declarations

Author contributions

WLH, writing—original draft preparation; MN, review and editing; EI, review and editing; TY, supervision.

Conflicts of interest

The authors declare no conflict of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by Ministry of Science and Technology of Taiwan, MOST 109-2314-B-037-143. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. [DOI] [PubMed]

Nag S, Qin J, Srivenugopal KS, Wang M, Zhang R. The MDM2-p53 pathway revisited. J Biomed Res. 2013;27:254–71. [DOI] [PubMed] [PMC]

Pribluda A, Elyada E, Wiener Z, Hamza H, Goldstein RE, Biton M, et al. A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell. 2013;24:242–56. [DOI] [PubMed]

Ou HL, Schumacher B. DNA damage responses and p53 in the aging process. Blood. 2018;131:488–95. [DOI] [PubMed] [PMC]

Barja G. Updating the mitochondrial free radical theory of aging: an integrated view, key aspects, and confounding concepts. Antioxid Redox Signal. 2013;19:1420–45. [DOI] [PubMed] [PMC]

Adam-Vizi V, Starkov AA. Calcium and mitochondrial reactive oxygen species generation: how to read the facts. J Alzheimers Dis. 2010;20 Suppl 2:S413–26. [DOI] [PubMed] [PMC]

Bong AHL, Monteith GR. Calcium signaling and the therapeutic targeting of cancer cells. Biochim Biophys Acta Mol Cell Res. 2018;1865:1786–94. [DOI] [PubMed]

Santoni G, Morelli MB, Marinelli O, Nabissi M, Santoni M, Amantini C. Calcium signaling and the regulation of chemosensitivity in cancer cells: role of the transient receptor potential channels. Adv Exp Med Biol. 2020;1131:505–17. [DOI] [PubMed]

Roberts-Thomson SJ, Chalmers SB, Monteith GR. The calcium-dignaling toolkit in cancer: remodeling and targeting. Cold Spring Harb Perspect Biol. 2019;11:a035204. [DOI] [PubMed] [PMC]

10.

Gregório C, Soares-Lima SC, Alemar B, Recamonde-Mendoza M, Camuzi D, de Souza-Santos PT, et al. Calcium signaling alterations caused by epigenetic mechanisms in pancreatic cancer: from early markers to prognostic impact. Cancers (Basel). 2020;12:1735. [DOI]

11.

Riera CE, Huising MO, Follett P, Leblanc M, Halloran J, Van Andel R, et al. TRPV1 pain receptors regulate longevity and metabolism by neuropeptide signaling. Cell. 2014;157:1023–36. [DOI] [PubMed]

12.

Borbély E, Payrits M, Hunyady A, Mező G, Pintér E. Important regulatory function of transient receptor potential ankyrin 1 receptors in age-related learning and memory alterations of mice. Geroscience. 2019;41:643–54. [DOI] [PubMed] [PMC]

13.

Hsu WL, Tsai MH, Wu CY, Liang JL, Lu JH, Kahle JS, et al. Nociceptive transient receptor potential canonical 7 (TRPC7) mediates aging-associated tumorigenesis induced by ultraviolet B. Aging Cell. 2020;19:e13075. [DOI] [PubMed] [PMC]

14.

Alcalde I, Iñigo-Portugués A, González-González O, Almaraz L, Artime E, Morenilla-Palao C, et al. Morphological and functional changes in TRPM8-expressing corneal cold thermoreceptor neurons during aging and their impact on tearing in mice. J Comp Neurol. 2018;526:1859–74. [DOI] [PubMed]

15.

Duitama M, Vargas-Lopez V, Casas Z, Albarracin SL, Sutachan JJ, Torres YP. TRP channels role in pain associated with neurodegenerative diseases. Front Neurosci. 2020;14:782. [DOI] [PubMed] [PMC]

16.

Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem. 2007;76:387–417. [DOI] [PubMed] [PMC]

17.

Prevarskaya N, Zhang L, Barritt G. TRP channels in cancer. Biochim Biophys Acta. 2007;1772:937–46. [DOI] [PubMed]

18.

Mickle AD, Shepherd AJ, Mohapatra DP. Nociceptive TRP channels: sensory detectors and transducers in multiple pain pathologies. Pharmaceuticals (Basel). 2016;9:72. [DOI]

19.

Gonzalez-Ramirez R, Chen Y, Liedtke WB, Morales-Lazaro SL. TRP Channels and Pain. In: Emir TLR, editor. Neurobiology of TRP channels. Boca Raton (FL): CRC Press/Taylor & Francis; 2017. pp. 125–48.

20.

Milici A, Talavera K. TRP channels as cellular targets of particulate matter. Int J Mol Sci. 2021;22:2783. [DOI] [PubMed] [PMC]

21.

Veldhuis NA, Poole DP, Grace M, McIntyre P, Bunnett NW. The G protein-coupled receptor-transient receptor potential channel axis: molecular insights for targeting disorders of sensation and inflammation. Pharmacol Rev. 2015;67:36–73. [DOI] [PubMed]

22.

Miller BA, Zhang W. TRP channels as mediators of oxidative stress. Adv Exp Med Biol. 2011;704:531–44. [DOI] [PubMed]

23.

Cuollo L, Antonangeli F, Santoni A, Soriani A. The senescence-associated secretory phenotype (SASP) in the challenging future of cancer therapy and age-related diseases. Biology (Basel). 2020;9:485. [DOI] [PubMed] [PMC]

24.

Yang RC, Hsu WL, Yoshoioka T. A novel concept on the repetitive calcium elevation. In: Yamaguchi M, editor. Recent developments in calcium signaling. New York: Nova Science Publishers, Inc.; 2014. pp. 67–87.

25.

Kunzelmann K. Ion channels and cancer. J Membr Biol. 2005;205:159–73. [DOI] [PubMed]

26.

Lehen’kyi V, Shapovalov G, Skryma R, Prevarskaya N. Ion channels and transporters in cancer. 5. Ion channels in control of cancer and cell apoptosis. Am J Physiol Cell Physiol. 2011;301:C1281–9. [DOI] [PubMed]

27.

Ito E, Hsu WL, Yoshioka T. A role for proton signaling in the induction of somatic cells to pluripotent embryonic stem cells. J Phys Chem Biophys. 2014;4:1000138.

28.

Lang F, Stournaras C. Ion channels in cancer: future perspectives and clinical potential. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130108. [DOI] [PubMed] [PMC]

29.

Wijerathne TD, Kim J, Yang D, Lee KP. Intracellular calcium-dependent regulation of the sperm-specific calcium-activated potassium channel, hSlo3, by the BK_Ca activator LDD175. Korean J Physiol Pharmacol. 2017;21:241–9. [DOI] [PubMed] [PMC]

30.

Merta PJ, Fullerton GD, Cameron IL. Characterization of water in unfertilized and fertilized sea urchin eggs. J Cell Physiol. 1986;127:439–47. [DOI] [PubMed]

31.

Wang Y, Han Y, Zhang Z. Experimental study on the effect of potassium chloride’s content on the ice melting rate. IOP Conf Ser: Earth Environ Sci. 2018;170:052020. [DOI]

32.

Webb DJ, Nuccitelli R. Direct measurement of intracellular pH changes in Xenopus eggs at fertilization and cleavage. J Cell Biol. 1981;91:562–7. [DOI] [PubMed] [PMC]

33.

Santoni G, Maggi F, Morelli MB, Santoni M, Marinelli O. Transient receptor potential cation channels in cancer therapy. Med Sci (Basel). 2019;7:108. [DOI]

34.

Wang YY, Zhao R, Zhe H. The emerging role of CaMKII in cancer. Oncotarget. 2015;6:11725–34. [DOI] [PubMed] [PMC]

35.

Riganti C, Doublier S, Viarisio D, Miraglia E, Pescarmona G, Ghigo D, et al. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Br J Pharmacol. 2009;156:1054–66. [DOI] [PubMed] [PMC]

36.

Aroke EN, Powell-Roach KL, Jaime-Lara RB, Tesfaye M, Roy A, Jackson P, et al. Taste the pain: the role of TRP channels in pain and taste perception. Int J Mol Sci. 2020;21:5929. [DOI]

37.

Alessandri-Haber N, Dina OA, Chen X, Levine JD. TRPC1 and TRPC6 channels cooperate with TRPV4 to mediate mechanical hyperalgesia and nociceptor sensitization. J Neurosci. 2009;29:6217–28. [DOI] [PubMed] [PMC]

38.

Ding X, He Z, Zhou K, Cheng J, Yao H, Lu D, et al. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. J Natl Cancer Inst. 2010;102:1052–68. [DOI] [PubMed]

39.

Quick K, Zhao J, Eijkelkamp N, Linley JE, Rugiero F, Cox JJ, et al. TRPC3 and TRPC6 are essential for normal mechanotransduction in subsets of sensory neurons and cochlear hair cells. Open Biol. 2012;2:120068. [DOI] [PubMed] [PMC]

40.

Wang Y, Qi YX, Qi Z, Tsang SY. TRPC3 regulates the proliferation and apoptosis resistance of triple negative breast cancer cells through the TRPC3/RASA4/MAPK pathway. Cancers (Basel). 2019;11:558. [DOI]

41.

Ota W, Nakane Y, Kashio M, Suzuki Y, Nakamura K, Mori Y, et al. Involvement of TRPM2 and TRPM8 in temperature-dependent masking behavior. Sci Rep. 2019;9:3706. [DOI] [PubMed] [PMC]

42.

Kelemen B, Pinto S, Kim N, Lisztes E, Hanyicska M, Vladar A, et al. The TRPM3 ion channel mediates nociception but not itch evoked by endogenous pruritogenic mediators. Biochem Pharmacol. 2021;183:114310. [DOI] [PubMed] [PMC]

43.

Levine JD, Alessandri-Haber N. TRP channels: targets for the relief of pain. Biochim Biophys Acta. 2007;1772:989–1003. [DOI] [PubMed]

44.

Orfanelli U, Jachetti E, Chiacchiera F, Grioni M, Brambilla P, Briganti A, et al. Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. Oncogene. 2015;34:2094–102. [DOI] [PubMed]

45.

Lin R, Wang Y, Chen Q, Liu Z, Xiao S, Wang B, et al. TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinoma. Mol Med Rep. 2018;17:7537–44. [DOI] [PubMed] [PMC]

46.

Siveen KS, Nizamuddin PB, Uddin S, Al-Thani M, Frenneaux MP, Janahi IA, et al. TRPV2: a cancer biomarker and potential therapeutic target. Dis Markers. 2020;2020:8892312. [DOI] [PubMed] [PMC]

47.

Shapovalov G, Ritaine A, Skryma R, Prevarskaya N. Role of TRP ion channels in cancer and tumorigenesis. Semin Immunopathol. 2016;38:357–69. [DOI] [PubMed]

48.

Izquierdo-Torres E, Hernández-Oliveras A, Fuentes-García G, Zarain-Herzberg Á. Calcium signaling and epigenetics: a key point to understand carcinogenesis. Cell Calcium. 2020;91:102285. [DOI] [PubMed]

49.

Margueron R, Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet. 2010;11:285–96. [DOI] [PubMed] [PMC]

50.

Biswas S, Rao CM. Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy. Eur J Pharmacol. 2018;837:8–24. [DOI] [PubMed]

51.

Hong S, Zheng G, Wiley JW. Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system. Gastroenterology. 2015;148:148–57.e7. [DOI] [PubMed] [PMC]

52.

Akari Y, Tadashi T, Yuichi A, Tomoyuki M, Masatoshi T, Tomoyuki K. TRPV1 is involved in both tumor growth and cancer-induced pain. American Society of Anesthesiologists 2019: The anesthesiology annual meeting; 2019 Oct 20; Florida, USA.

53.

Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA, et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest. 2006;116:3114–26. [DOI] [PubMed] [PMC]

54.

Kim JH, Hwang KH, Eom M, Kim M, Park EY, Jeong Y, et al. WNK1 promotes renal tumor progression by activating TRPC6-NFAT pathway. FASEB J. 2019;33:8588–99. [DOI] [PubMed]

55.

Lahue RS, Frizzell A. Histone deacetylase complexes as caretakers of genome stability. Epigenetics. 2012;7:806–10. [DOI] [PubMed] [PMC]

56.

Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26:5420–32. [DOI] [PubMed]

57.

Kim JM, Heo K, Choi J, Kim K, An W. The histone variant MacroH2A regulates Ca²⁺ influx through TRPC3 and TRPC6 channels. Oncogenesis. 2013;2:e77. [DOI] [PubMed] [PMC]

58.

Dimaras H, Corson TW. Retinoblastoma, the visible CNS tumor: a review. J Neurosci Res. 2019;97:29–44. [DOI] [PubMed] [PMC]

59.

Benavente CA, Dyer MA. Genetics and epigenetics of human retinoblastoma. Annu Rev Pathol. 2015;10:547–62. [DOI] [PubMed]

60.

Mergler S, Cheng Y, Skosyrski S, Garreis F, Pietrzak P, Kociok N, et al. Altered calcium regulation by thermosensitive transient receptor potential channels in etoposide-resistant WERI-Rb1 retinoblastoma cells. Exp Eye Res. 2012;94:157–73. [DOI] [PubMed]

61.

Tieva A, Peltomäki P. Epigenetic modifications in cancer. Duodecim. 2012;128:62–71. (in Finnish) [PubMed]

62.

Lee CJ, Ahn H, Jeong D, Pak M, Moon JH, Kim S. Impact of mutations in DNA methylation modification genes on genome-wide methylation landscapes and downstream gene activations in pan-cancer. BMC Med Genomics. 2020;13 Suppl 3:27. [DOI] [PubMed] [PMC]

63.

Hsu WL, Lu JH, Noda M, Wu CY, Liu JD, Sakakibara M, et al. Derinat protects skin against ultraviolet-B (UVB)-induced cellular damage. Molecules. 2015;20:20297–311. [DOI] [PubMed] [PMC]

64.

Yang Y, Zhu Y, Xi X. Anti-inflammatory and antitumor action of hydrogen via reactive oxygen species. Oncol Lett. 2018;16:2771–6. [DOI] [PubMed] [PMC]

65.

Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, et al. Resveratrol: a double-edged sword in health benefits. Biomedicines. 2018;6:91. [DOI]

66.

Wu MS, Aquino LBB, Barbaza MYU, Hsieh CL, Castro-Cruz KA, Yang LL, et al. Anti-inflammatory and anticancer properties of bioactive compounds from Sesamum indicum L.—a review. Molecules. 2019;24:4426. [DOI]

67.

Ghosh R, Alajbegovic A, Gomes AV. NSAIDs and cardiovascular diseases: role of reactive oxygen species. Oxid Med Cell Longev. 2015;2015:536962. [DOI] [PubMed] [PMC]

68.

Bhattacharyya S, Ghosh S, Sil PC. Amelioration of aspirin induced oxidative impairment and apoptotic cell death by a novel antioxidant protein molecule isolated from the herb Phyllanthus niruri. PLoS One. 2014;9:e89026. [DOI] [PubMed] [PMC]

69.

Croteau DL, Fang EF, Nilsen H, Bohr VA. NAD⁺ in DNA repair and mitochondrial maintenance. Cell Cycle. 2017;16:491–2. [DOI] [PubMed] [PMC]

70.

Song J, Li J, Yang F, Ning G, Zhen L, Wu L, et al. Nicotinamide mononucleotide promotes osteogenesis and reduces adipogenesis by regulating mesenchymal stromal cells via the SIRT1 pathway in aged bone marrow. Cell Death Dis. 2019;10:336. [DOI] [PubMed] [PMC]

71.

Meng Y, Ren Z, Xu F, Zhou X, Song C, Wang VY, et al. Nicotinamide promotes cell survival and differentiation as kinase inhibitor in human pluripotent stem cells. Stem Cell Reports. 2018;11:1347–56. [DOI] [PubMed] [PMC]

72.

Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24:795–806. [DOI] [PubMed] [PMC]

73.

Kim YG, Choi J, Kim K. Mesenchymal stem cell-derived exosomes for effective cartilage tissue repair and treatment of osteoarthritis. Biotechnol J. 2020;15:e2000082. [DOI] [PubMed]

74.

Liu Y, Ma Y, Zhang J, Yuan Y, Wang J. Exosomes: a novel therapeutic agent for cartilage and bone tissue regeneration. Dose Response. 2019;17:1559325819892702. [DOI]

75.

Zhou J, Zhou XA, Zhang N, Wang J. Evolving insights: how DNA repair pathways impact cancer evolution. Cancer Biol Med. 2020;17:805–27. [DOI] [PubMed] [PMC]

76.

Zhao R, Chen X, Song H, Bie Q, Zhang B. Dual role of MSC-derived exosomes in tumor development. Stem Cells Int. 2020;2020:8844730. [DOI] [PubMed] [PMC]

77.

Chiarugi A, Dolle C, Felici R, Ziegler M. The NAD metabolome-a key determinant of cancer cell biology. Nat Rev Cancer. 2012;12:741–52. [DOI] [PubMed]

78.

Li L, Chen C, Chiang C, Xiao T, Chen Y, Zhao Y, et al. The impact of TRPV1 on cancer pathogenesis and therapy: a systematic review. Int J Biol Sci. 2021;17:2034–49. [DOI] [PubMed] [PMC]

79.

Weber LV, Al-Refae K, Wölk G, Bonatz G, Altmüller J, Becker C, et al. Expression and functionality of TRPV1 in breast cancer cells. Breast Cancer (Dove Med Press). 2016;8:243–52. [DOI] [PubMed] [PMC]

80.

Amantini C, Mosca M, Nabissi M, Lucciarini R, Caprodossi S, Arcella A, et al. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J Neurochem. 2007;102:977–90. [DOI] [PubMed]

81.

Boonen B, Alpizar YA, Meseguer VM, Talavera K. TRP channels as sensors of bacterial endotoxins. Toxins (Basel). 2018;10:836. [DOI]

82.

Wu YT, Yen SL, Li CF, Chan TC, Chen TJ, Lee SW, et al. Overexpression of transient receptor protein cation channel subfamily a member 1, confers an independent prognostic indicator in nasopharyngeal carcinoma. J Cancer. 2016;7:1181–8. [DOI] [PubMed] [PMC]

83.

Casciano JC, Duchemin NJ, Lamontagne RJ, Steel LF, Bouchard MJ. Hepatitis B virus modulates store-operated calciumentrytoenhanceviral replicationin primary hepatocytes. PLoS One. 2017;12:e0168328. [DOI] [PubMed] [PMC]

84.

Goldenberg NM, Wang L, Ranke H, Liedtke W, Tabuchi A, Kuebler WM. TRPV4 is required for hypoxic pulmonary vasoconstriction. Anesthesiology. 2015;122:1338–48. [DOI] [PubMed]

85.

Steinritz D, Stenger B, Dietrich A, Gudermann T, Popp T. TRPs in tox: involvement of transient receptor potential-channels in chemical-induced organ toxicity—a structured review. Cells. 2018;7:98. [DOI]

86.

Ernst J, Grabiec U, Falk K, Dehghani F, Schaedlich K. The endocrine disruptor DEHP and the ECS: analysis of a possible crosstalk. Endocr Connect. 2020;9:101–10. [DOI] [PubMed] [PMC]

87.

Liu C, Montell C. Forcing open TRP channels: mechanical gating as a unifying activation mechanism. Biochem Biophys Res Commun. 2015;460:22–5. [DOI] [PubMed] [PMC]

88.

Bellono NW, Kammel LG, Zimmerman AL, Oancea E. UV light phototransduction activates transient receptor potential A1 ion channels in human melanocytes. Proc Natl Acad Sci U S A. 2013;110:2383–8. [DOI] [PubMed] [PMC]

89.

Takahashi N, Chen HY, Harris IS, Stover DG, Selfors LM, Bronson RT, et al. Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance. Cancer Cell. 2018;33:985–1003.e7. [DOI] [PubMed] [PMC]

90.

Cojocaru F, Şelescu T, Domocoş D, Măruţescu L, Chiritoiu G, Chelaru NR, et al. Functional expression of the transient receptor potential ankyrin type 1 channel in pancreatic adenocarcinoma cells. Sci Rep. 2021;11:2018. [DOI] [PubMed] [PMC]

91.

Elzamzamy OM, Penner R, Hazlehurst LA. The role of TRPC1 in modulating cancer progression. Cells. 2020;9:388. [DOI]

92.

Zhang Z, Ren L, Zhao Q, Lu G, Ren M, Lu X, et al. TRPC1 exacerbate metastasis in gastric cancer via ciRS-7/miR-135a-5p/TRPC1 axis. Biochem Biophys Res Commun. 2020;529:85–90. [DOI] [PubMed]

93.

Tao X, Zhao N, Jin H, Zhang Z, Liu Y, Wu J, et al. FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. Endocr Relat Cancer. 2013;20:415–29. [DOI] [PubMed] [PMC]

94.

Chen Z, Zhu Y, Dong Y, Zhang P, Han X, Jin J, et al. Overexpression of TrpC5 promotes tumor metastasis via the HIF-1α-Twist signaling pathway in colon cancer. Clin Sci (Lond). 2017;131:2439–50. [DOI] [PubMed]

95.

Zhang P, Liu X, Li H, Chen Z, Yao X, Jin J, et al. TRPC5-induced autophagy promotes drug resistance in breast carcinoma via CaMKKβ/AMPKα/mTOR pathway. Sci Rep. 2017;7:3158. [DOI] [PubMed] [PMC]

96.

Guilbert A, Dhennin-Duthille I, Hiani YE, Haren N, Khorsi H, Sevestre H, et al. Expression of TRPC6 channels in human epithelial breast cancer cells. BMC Cancer. 2008;8:125. [DOI] [PubMed] [PMC]

97.

El Boustany C, Bidaux G, Enfissi A, Delcourt P, Prevarskaya N, Capiod T. Capacitative calcium entry and transient receptor potential canonical 6 expression control human hepatoma cell proliferation. Hepatology. 2008;47:2068–77. [DOI] [PubMed]

98.

Cai R, Ding X, Zhou K, Shi Y, Ge R, Ren G, et al. Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells. Int J Cancer. 2009;125:2281–7. [DOI] [PubMed]

99.

Zhang SS, Wen J, Yang F, Cai XL, Yang H, Luo KJ, et al. High expression of transient potential receptor C6 correlated with poor prognosis in patients with esophageal squamous cell carcinoma. Med Oncol. 2013;30:607. [DOI] [PubMed]

100.

Yue D, Wang Y, Xiao JY, Wang P, Ren CS. Expression of TRPC6 in benign and malignant human prostate tissues. Asian J Androl. 2009;11:541–7. [DOI] [PubMed] [PMC]

101.

Chigurupati S, Venkataraman R, Barrera D, Naganathan A, Madan M, Paul L, et al. Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. Cancer Res. 2010;70:418–27. [DOI] [PubMed]

102.

Sumoza-Toledo A, Espinoza-Gabriel MI, Montiel-Condado D. Evaluation of the TRPM2 channel as a biomarker in breast cancer using public databases analysis. Bol Med Hosp Infant Mex. 2016;73:397–404. [DOI] [PubMed]

103.

Huang C, Qin Y, Liu H, Liang N, Chen Y, Ma D, et al. Downregulation of a novel long noncoding RNA TRPM2-AS promotes apoptosis in non-small cell lung cancer. Tumour Biol. 2017;39:1010428317691191. [DOI]

104.

Almasi S, Sterea AM, Fernando W, Clements DR, Marcato P, Hoskin DW, et al. TRPM2 ion channel promotes gastric cancer migration, invasion and tumor growth through the AKT signaling pathway. Sci Rep. 2019;9:4182. [DOI] [PubMed] [PMC]

105.

Xu C, Huang Q, Zhang C, Xu W, Xu G, Zhao X, et al. Long non-coding RNA TRPM2-AS as a potential biomarker for hepatocellular carcinoma. Ir J Med Sci. 2018;187:621–8. [DOI] [PubMed]

106.

Zhao LY, Xu WL, Xu ZQ, Qi C, Li Y, Cheng J, et al. The overexpressed functional transient receptor potential channel TRPM2 in oral squamous cell carcinoma. Sci Rep. 2016;6:38471. [DOI] [PubMed] [PMC]

107.

Alptekin M, Eroglu S, Tutar E, Sencan S, Geyik MA, Ulasli M, et al. Gene expressions of TRP channels in glioblastoma multiforme and relation with survival. Tumour Biol. 2015;36:9209–13. [DOI] [PubMed]

108.

Hall DP, Cost NG, Hegde S, Kellner E, Mikhaylova O, Stratton Y, et al. TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell. 2014;26:738–53. [DOI] [PubMed] [PMC]

109.

Santoni G, Farfariello V. TRP channels and cancer: new targets for diagnosis and chemotherapy. Endocr Metab Immune Disord Drug Targets. 2011;11:54–67. [DOI] [PubMed]

110.

Yee NS. Roles of TRPM8 Ion channels in cancer: proliferation, survival, and invasion. Cancers (Basel). 2015;7:2134–46. [DOI] [PubMed] [PMC]

111.

Stoklosa P, Borgstrom A, Kappel S, Peinelt C. TRP channels in digestive tract cancers. Int J Mol Sci. 2020;21:1877. [DOI]

112.

Lan X, Zhao J, Song C, Yuan Q, Liu X. TRPM8 facilitates proliferation and immune evasion of esophageal cancer cells. Biosci Rep. 2019;39:BSR20191878. [DOI] [PubMed] [PMC]

113.

Zeng J, Wu Y, Zhuang S, Qin L, Hua S, Mungur R, et al. Identification of the role of TRPM8 in glioblastoma and its effect on proliferation, apoptosis and invasion of the U251 human glioblastoma cell line. Oncol Rep. 2019;42:1517–26. [DOI] [PubMed]

114.

Lozano C, Córdova C, Marchant I, Zúñiga R, Ochova P, Ramírez-Barrantes R, et al. Intracellular aggregated TRPV1 is associated with lower survival in breast cancer patients. Breast Cancer (Dove Med Press). 2018;10:161–8. [DOI] [PubMed] [PMC]

115.

Marincsák R, Tóth BI, Czifra G, Márton I, Rédl P, Tar I, et al. Increased expression of TRPV1 in squamous cell carcinoma of the human tongue. Oral Dis. 2009;15:328–35. [DOI] [PubMed]

116.

So CL, Milevskiy MJG, Monteith GR. Transient receptor potential cation channel subfamily V and breast cancer. Lab Invest. 2020;100:199–206. [DOI] [PubMed]

117.

Ren X, Hao W, Liu J, Li Y, Wang B, Zu X, et al. Study on the clinical significance of TRPV2 and MMP2 expressions in ovarian cancer. BIOCELL. 2021;45:521–6. [DOI]

118.

Li X, Zhang Q, Fan K, Li B, Li H, Qi H, et al. Overexpression of TRPV3 correlates with tumor progression in non-small cell lung cancer. Int J Mol Sci. 2016;17:437. [DOI] [PubMed] [PMC]

119.

Yu S, Huang S, Ding Y, Wang W, Wang A, Lu Y. Transient receptor potential ion-channel subfamily V member 4: a potential target for cancer treatment. Cell Death Dis. 2019;10:497. [DOI] [PubMed] [PMC]

120.

Wang H, Zhang B, Wang X, Mao J, Li W, Sun Y, et al. TRPV4 overexpression promotes metastasis through epithelial-mesenchymal transition in gastric cancer and correlates with poor prognosis. Onco Targets Ther. 2020;13:8383–94. [DOI] [PubMed] [PMC]

121.

Liu X, Zhang P, Xie C, Sham KWY, Ng SSM, Chen Y, et al. Activation of PTEN by inhibition of TRPV4 suppresses colon cancer development. Cell Death Dis. 2019;10:460. [DOI] [PubMed] [PMC]

122.

Yang W, Wu PF, Ma JX, Liao MJ, Xu LS, Yi L. TRPV4 activates the Cdc42/N-wasp pathway to promote glioblastoma invasion by altering cellular protrusions. Sci Rep. 2020;10:14151. [DOI] [PubMed] [PMC]